MedTech Innovator Xyall Secures €7.6M for Global Lab Automation
February 21, 2026, 4:07 pm
Location: Netherlands, North Brabant, Tilburg
Employees: 51-200
Founded date: 1983
Xyall secured €7.6 million. This significant investment drives the global rollout of its Tissector TableTop. The automated tissue dissection system revolutionizes molecular pathology workflows. It addresses long-standing challenges: manual subjectivity, diagnostic imprecision, and critical lab technician shortages. Xyall's innovation ensures faster, more accurate results. It fundamentally improves patient care, particularly for personalized oncology treatments. This crucial funding solidifies Xyall's market position. It meets urgent demands for scalable, reliable lab automation.
Xyall, an Eindhoven-based MedTech innovator, secured €7.6 million. This substantial investment powers the global expansion of its automated tissue dissection platforms. The funding round was led by Capricorn Partners. Other investors included Sioux Technologies, Brabant Development Agency (BOM), Health Investment Partners, and various private backers. This capital infusion accelerates the rollout of Xyall's Tissector TableTop.
Molecular pathology relies heavily on accurate tissue analysis. Traditional methods present significant hurdles. Pathologists manually mark regions of interest (ROIs) on slides. Lab technicians then scrape tissue from these marked areas. This process is highly subjective. It introduces a high risk of error. Cross-contamination also poses a threat. Such manual steps are time-consuming. They are difficult to scale. A global shortage of specialized lab technicians further complicates matters. This bottleneck impedes rapid diagnostic advancements.
Xyall's technology offers a critical solution. It digitizes and automates the entire tissue dissection workflow. The system combines high-resolution slide imaging. Precise image registration ensures accuracy. Workflow optimization streamlines operations. High-precision robotics execute delicate tasks flawlessly. This integration transforms a manual, error-prone step into an automated, reliable process.
The automated system directly tackles existing challenges. It ensures precise ROI determination. This reduces workload for lab technicians. Case processing becomes much faster. The risk of cross-contamination is eliminated. Ultimately, Xyall delivers more reliable molecular diagnostic test results. This is crucial for modern medicine.
Xyall launched its first solution, the Tissector High Throughput System, in 2021. This system targets large molecular laboratories. It handles high-volume molecular diagnostics. The unit holds 1,800 slides. It dissects over 80 slides per hour. Accuracy exceeds 0.1 mm. It operates unattended for three hours. This high-capacity system meets the demands of extensive research and clinical facilities.
In 2023, Xyall introduced the Tissector TableTop. This compact solution caters to small and medium-sized molecular pathology laboratories. It accommodates 72 slides. Dissection occurs at over 30 slides per hour. Accuracy is impressive, at ≤ 0.1 mm. It runs for more than two uninterrupted hours. The TableTop brings advanced automation to a broader range of labs. Its design addresses practical operational challenges.
Molecular diagnostics are pivotal for treatment decisions. This is especially true in oncology. Personalized treatment plans depend on precise molecular insights. Laboratories face immense pressure. They must deliver results with greater speed and accuracy. Simultaneously, they contend with an acute shortage of skilled staff. Xyall's automated solutions directly address these urgent needs.
The Tissector TableTop already sees significant deployment. Over 15 molecular pathology laboratories utilize the system. These include leading commercial, academic, pharmaceutical, and research institutions. Many are located in the United States. This rapid adoption validates the technology's clinical relevance. It underscores its operational value in diverse settings. The market clearly demands scalable, reliable automation.
The investment consortium recognized Xyall's potential. Capricorn Partners highlighted the company's ability to boost lab efficiency. They also noted the evidence supporting more accurate diagnoses. This is vital for fields like oncology. Better diagnoses lead to better personalized treatment plans. Investors see Xyall poised for rapid growth. Growth is expected across both research and clinical laboratories. This funding will accelerate Xyall's development. It will solidify its position as a global leader.
Xyall's technology bridges a critical gap. It connects morphological assessment with advanced molecular diagnostics. PCR and next-generation sequencing technologies have advanced rapidly. Yet, the tissue selection step remained largely manual. Xyall provides the missing link. It ensures that the initial tissue analysis matches the sophistication of downstream molecular tests. This integration is essential for advancing diagnostic capabilities.
The impact extends beyond lab efficiency. Xyall's solutions enhance the quality of healthcare. They improve accessibility to advanced diagnostics. Accurate molecular pathology supports better patient outcomes worldwide. The company shows impressive commercial traction. Its technological capabilities continue to grow. This global potential drives investor confidence. Xyall is set to scale its impact in molecular pathology. Its innovative systems are transforming the diagnostic landscape. This marks a new era for precision medicine.
Xyall, an Eindhoven-based MedTech innovator, secured €7.6 million. This substantial investment powers the global expansion of its automated tissue dissection platforms. The funding round was led by Capricorn Partners. Other investors included Sioux Technologies, Brabant Development Agency (BOM), Health Investment Partners, and various private backers. This capital infusion accelerates the rollout of Xyall's Tissector TableTop.
Molecular pathology relies heavily on accurate tissue analysis. Traditional methods present significant hurdles. Pathologists manually mark regions of interest (ROIs) on slides. Lab technicians then scrape tissue from these marked areas. This process is highly subjective. It introduces a high risk of error. Cross-contamination also poses a threat. Such manual steps are time-consuming. They are difficult to scale. A global shortage of specialized lab technicians further complicates matters. This bottleneck impedes rapid diagnostic advancements.
Xyall's technology offers a critical solution. It digitizes and automates the entire tissue dissection workflow. The system combines high-resolution slide imaging. Precise image registration ensures accuracy. Workflow optimization streamlines operations. High-precision robotics execute delicate tasks flawlessly. This integration transforms a manual, error-prone step into an automated, reliable process.
The automated system directly tackles existing challenges. It ensures precise ROI determination. This reduces workload for lab technicians. Case processing becomes much faster. The risk of cross-contamination is eliminated. Ultimately, Xyall delivers more reliable molecular diagnostic test results. This is crucial for modern medicine.
Xyall launched its first solution, the Tissector High Throughput System, in 2021. This system targets large molecular laboratories. It handles high-volume molecular diagnostics. The unit holds 1,800 slides. It dissects over 80 slides per hour. Accuracy exceeds 0.1 mm. It operates unattended for three hours. This high-capacity system meets the demands of extensive research and clinical facilities.
In 2023, Xyall introduced the Tissector TableTop. This compact solution caters to small and medium-sized molecular pathology laboratories. It accommodates 72 slides. Dissection occurs at over 30 slides per hour. Accuracy is impressive, at ≤ 0.1 mm. It runs for more than two uninterrupted hours. The TableTop brings advanced automation to a broader range of labs. Its design addresses practical operational challenges.
Molecular diagnostics are pivotal for treatment decisions. This is especially true in oncology. Personalized treatment plans depend on precise molecular insights. Laboratories face immense pressure. They must deliver results with greater speed and accuracy. Simultaneously, they contend with an acute shortage of skilled staff. Xyall's automated solutions directly address these urgent needs.
The Tissector TableTop already sees significant deployment. Over 15 molecular pathology laboratories utilize the system. These include leading commercial, academic, pharmaceutical, and research institutions. Many are located in the United States. This rapid adoption validates the technology's clinical relevance. It underscores its operational value in diverse settings. The market clearly demands scalable, reliable automation.
The investment consortium recognized Xyall's potential. Capricorn Partners highlighted the company's ability to boost lab efficiency. They also noted the evidence supporting more accurate diagnoses. This is vital for fields like oncology. Better diagnoses lead to better personalized treatment plans. Investors see Xyall poised for rapid growth. Growth is expected across both research and clinical laboratories. This funding will accelerate Xyall's development. It will solidify its position as a global leader.
Xyall's technology bridges a critical gap. It connects morphological assessment with advanced molecular diagnostics. PCR and next-generation sequencing technologies have advanced rapidly. Yet, the tissue selection step remained largely manual. Xyall provides the missing link. It ensures that the initial tissue analysis matches the sophistication of downstream molecular tests. This integration is essential for advancing diagnostic capabilities.
The impact extends beyond lab efficiency. Xyall's solutions enhance the quality of healthcare. They improve accessibility to advanced diagnostics. Accurate molecular pathology supports better patient outcomes worldwide. The company shows impressive commercial traction. Its technological capabilities continue to grow. This global potential drives investor confidence. Xyall is set to scale its impact in molecular pathology. Its innovative systems are transforming the diagnostic landscape. This marks a new era for precision medicine.